1. Home
  2. PLSE vs DMRA Comparison

PLSE vs DMRA Comparison

Compare PLSE & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$25.48

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.85

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLSE
DMRA
Founded
2014
2011
Country
United States
United States
Employees
N/A
7
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PLSE
DMRA
Price
$25.48
$24.85
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$22.00
$43.00
AVG Volume (30 Days)
338.8K
283.8K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$16.50
52 Week High
$27.98
$28.76

Technical Indicators

Market Signals
Indicator
PLSE
DMRA
Relative Strength Index (RSI) 59.22 50.39
Support Level $17.58 $24.80
Resistance Level $27.14 $26.73
Average True Range (ATR) 1.84 1.64
MACD 0.49 -0.01
Stochastic Oscillator 73.39 57.63

Price Performance

Historical Comparison
PLSE
DMRA

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: